BioSpace News Archive

NeoImmuneTech, Inc. (NIT), a clinical-stage T cell focused biopharmaceutical company, today announced it has received notice of approval from the Korea Exchange (KRX) for its initial public offering (IPO) on the Korean Securities Dealers Automated Quotations (KOSDAQ).

ChoiceSpine LLC, a privately held spinal device manufacturer based in Knoxville, TN, successfully announces 3,000 implantations of their innovative 3D Printed Tiger Shark interbody family.

Shimadzu Medical Systems USA announces the North America sales release of our newest general radiography solution, RADspeed Pro style edition with GLIDE Technology™

Hancock Jaffe Laboratories, Inc., a developer of medical devices that restore cardiac and vascular health, announced that Dr. Hamed Alavi has been promoted to Vice President of Research and Development and Quality and that Craig Glynn has accepted the position of Chief Financial Officer.

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference.

Pure Extracts Technologies Corp . (CSE: PULL) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company, is pleased to announce that it is commencing a study on the formulation and manufacturing of psilocybin based active treatments for oral tablets, capsules and a nasal gel that will be used as an investigational product. The study with be conducted at the Toronto Institute of Pharmaceutical Technology (

Orexo AB, announces that the US Patent and Trademark Office has issued an additional patent for ZUBSOLV®, Orexo’s sublingual buprenorphine and naloxone tablet for the treatment of opioid use disorder.

DPW Holdings Announces Alzamend Neuro ® , Inc.’s Confidential Submission of a Draft Registration Statement Relating to the Proposed Initial Public Offering of Its Common Stock NEWPORT BEACH, Calif.--( BUSINESS WIRE )-- DPW Holdings, Inc. (NYSE American: DPW), a diversified holding company (“ DPW ,” or the “ Company ”), announced that Alzamend Neuro®, Inc. (“ Alzamend ”) today announced that it has confidentially submitted a draft registration statement on

– exoIL-12 resulted in no local or systemic treatment-related adverse events – – Local administration of exoIL-12 demonstrated no systemic exposure to IL-12 – – Dose selection data and advancement into multi-dose study in cutaneous T cell lymphoma patients anticipated in Q1 2021 –

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), today announced that the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland has granted an additional new indication for DEXAVEN (dexamethasone phosphate) solution for injection, 4 mg/ml, for the treatment of COVID-19 in adult an